An immunological perspective is provided on how the breadth of rejection mechanisms that have been uncovered through decades of research and the relative simplicity of designing PSC immune evasion strategies to circumvent these mechanisms apply to the treatment of type 1 diabetes are discussed.
Abstract
Abstract Pluripotent stem cell (PSC)-based therapies hold the potential to unlock cures for numerous diseases, including, but not limited to, Parkinson’s disease, macular degeneration, heart failure, type 1 diabetes, and cancer. Yet as protocols to differentiate PSCs into therapeutically useful cell types have progressed rapidly, immunological rejection remains a major barrier that may limit the widespread use of such PSC-based therapies. In recent years, strategies to genetically modify PSCs to prevent immunological rejection of the downstream cell product have become a point of emphasis. Here, we provide an immunological perspective on these strategies, discussing the breadth of rejection mechanisms that have been uncovered through decades of research and the relative simplicity of designing PSC immune evasion strategies to circumvent these mechanisms. We focus in particular on how these strategies apply to the treatment of type 1 diabetes.
This review traces key field milestones and analyzes prospects and hurdles for next-generation iPSC therapies as autologous and allogeneic iPSC therapies complement each other for distinct clinical demands.
Anmin Wang, Yunpei Zhang, Hong-Kui Deng et al.· Cell Reports Medicine· 0 citations
This work proposes an integrated approach that combines modulation of programmed cell death pathways, targeted activation of RAS signaling, optimization of mitochondrial health, and use of biocompatible scaffolds to support neuronal maturation and network integration and provides a conceptual framework for improving th...
O. Chen, Kelvin K Hui, Fabian Raudzus et al.· Cell Death and Disease· 0 citations
This paper will provide the current information on stem cells used in the treatment of children and the many different types of stem cells, including: hematopoietic stem cells (and their derivatives), mesenchymal stem cells (and their derivatives), induced pluripotent stem cells, embryonic stem cells, tissue-specific p...
Hany E. Marei· Stem cell research & therape...· 0 citations
The article traces the trend of directed differentiation technologies evolving from two-dimensional culture to three-dimensional organoids and details their practical applications in diseases such as stroke, Alzheimer's disease, and spinal cord injury—particularly in spinal cord injury models, where transplanted cells...
Dai-Yi Yang· International Journal of Bio...· 0 citations
Key applications of iPSC technology in hemato-oncology are summarized, its major advantages and current limitations are discussed, and emerging directions are highlighted, including scalable iPSC-derived blood cell therapies for inherited and acquired bone marrow failure syndromes and leukemia.
Ivan Tesakov, M. Nasri, M. Klimiankou et al.· Frontiers in Immunology· 0 citations
A comprehensive literature review of preclinical models and clinical trials focusing on mesenchymal, hematopoietic, and pluripotent stem cells, evaluating their efficacy, safety, and manufacturing challenges found stem cell therapies demonstrate remarkable healing potential.
Somayeh Shamlou, H. Rostami, Ali Hassanzadeh et al.· Journal of Clinical and Tran...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
